Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
Zacks reports that Wall Street analysts’ average price target for Immunovant implies 30.5% potential upside. It notes the metric’s effectiveness is questionable, while positive earnings estimate revisions may point to upside.
Why it matters — IMVT watchers may note the analyst-target estimate and the cited positive trend in earnings estimate revisions, alongside the stated caveat about the metric.